Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine

Richard B. Kennedy

doi:10.1016/S0140-6736(21)02834-8

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine

General Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	212-213
Number of pages	2
Journal	The Lancet
Volume	399
Issue number	10321
DOIs	https://doi.org/10.1016/S0140-6736(21)02834-8
State	Published - Jan 15 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(21)02834-8

Cite this

@article{9cbdb91a2da649d59c2b921719d779a8,

title = "Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine",

author = "Kennedy, {Richard B.}",

year = "2022",

month = jan,

day = "15",

doi = "10.1016/S0140-6736(21)02834-8",

language = "English (US)",

volume = "399",

pages = "212--213",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10321",

}

TY - JOUR

T1 - Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine

AU - Kennedy, Richard B.

PY - 2022/1/15

Y1 - 2022/1/15

UR - http://www.scopus.com/inward/record.url?scp=85122688770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122688770&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(21)02834-8

DO - 10.1016/S0140-6736(21)02834-8

M3 - Comment/debate

C2 - 34953524

AN - SCOPUS:85122688770

SN - 0140-6736

VL - 399

SP - 212

EP - 213

JO - The Lancet

JF - The Lancet

IS - 10321

ER -

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this